# Study of Dexycu in Treating Intraocular Inflammation

> **NCT06429306** · PHASE3 · COMPLETED · sponsor: **Ocumension Therapeutics (Shanghai) Co., Ltd** · enrollment: 285 (actual)

## Conditions studied

- Inflammation
- Cataract

## Interventions

- **DRUG:** Dexycu
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06429306
- **Lead sponsor:** Ocumension Therapeutics (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-22
- **Primary completion:** 2023-11-24
- **Final completion:** 2024-04-09
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429306, "Study of Dexycu in Treating Intraocular Inflammation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06429306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*